Browse > Article
http://dx.doi.org/10.5223/pghn.2021.24.5.413

The Update of Treatment for Primary Intestinal Lymphangiectasia  

Kwon, Yiyoung (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Kim, Mi Jin (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Publication Information
Pediatric Gastroenterology, Hepatology & Nutrition / v.24, no.5, 2021 , pp. 413-422 More about this Journal
Abstract
Intestinal lymphangiectasia is a rare disease which is causing protein-losing enteropathy. Treatment of intestinal lymphangiectasia can be a challenge for clinicians because of the lack of specific guidelines regarding pharmacological indications. We sought to introduce a diagnostic approach and suggest guidelines for treatment. After exclusion of secondary intestinal lymphangiectasia, magnetic resonance lymphangiography is a promising tool for the assessment of abnormal lymphatic lesions in primary intestinal lymphangiectasia. Determining the extent of the lesion provides direction for treatment options. Focal short-segment intestinal lymphangiectasia can be treated via intestinal resection or radiologic embolization after dietary therapy failure. Diffuse intestinal lymphangiectasia and extensive lymphangiectasia should be treated with several drugs with a full understanding of their mechanisms.
Keywords
Lymphangiectasis; Therapeutic embolization; Octreotide; Sirolimus; Everolimus;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Thomas DW, Sinatra FR, Merritt RJ. Random fecal alpha-1-antitrypsin concentration in children with gastrointestinal disease. Gastroenterology 1981;80:776-82.   DOI
2 Kverneland LS, Kramer P, Ovroutski S. Five decades of the Fontan operation: a systematic review of international reports on outcomes after univentricular palliation. Congenit Heart Dis 2018;13:181-93.   DOI
3 Itkin M, Piccoli DA, Nadolski G, Rychik J, DeWitt A, Pinto E, et al. Protein-losing enteropathy in patients with congenital heart disease. J Am Coll Cardiol 2017;69:2929-37.   DOI
4 McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011;364:1595-606.   DOI
5 Altin Z, Atabay Y, Ozer S, Karakoyun M, Ekmekci S, Yurekli EY, et al. Primary intestinal lymphangiectasia and a review of the current literature. Turk J Gastroenterol 2018;29:714-6.
6 Crossland DS, Van De Bruaene A, Silversides CK, Hickey EJ, Roche SL. Heart failure in adult congenital heart disease: from advanced therapies to end-of-life care. Can J Cardiol 2019;35:1723-39.   DOI
7 Takeda H, Ishihama K, Fukui T, Fujishima S, Orii T, Nakazawa Y, et al. Significance of rapid turnover proteins in protein-losing gastroenteropathy. Hepatogastroenterology 2003;50:1963-5.
8 Bernier JJ, Florent C, Desmazures C, Aymes C, L'Hirondel C. Diagnosis of protein-losing enteropathy by gastrointestinal clearance of alpha1-antitrypsin. Lancet 1978;2:763-4.
9 Schmidt PN, Blirup-Jensen S, Svendsen PJ, Wandall JH. Characterization and quantification of plasma proteins excreted in faeces from healthy humans. Scand J Clin Lab Invest 1995;55:35-45.
10 Konar A, Brown CB, Hancock BW, Moss S. Protein losing enteropathy as a sole manifestation of nonHodgkin's lymphoma. Postgrad Med J 1986;62:399-400.   DOI
11 D'amico MA, Weiner M, Ruzal-Shapiro C, DeFelice AR, Brodlie S, Kazlow PG. Protein-losing enteropathy: an unusual presentation of neuroblastoma. Clin Pediatr (Phila) 2003;42:371-3.   DOI
12 Akkelle BS, Tutar E, Sengul OK, Celikel CA, Ertem D. A rare complication of giardiasis in children: protein-losing enteropathy. Pediatr Infect Dis J 2018;37:e345-7.   DOI
13 Braamskamp MJ, Dolman KM, Tabbers MM. Clinical practice. Protein-losing enteropathy in children. Eur J Pediatr 2010;169:1179-85.   DOI
14 Chavhan GB, Amaral JG, Temple M, Itkin M. MR lymphangiography in children: technique and potential applications. Radiographics 2017;37:1775-90.   DOI
15 MacLean JE, Cohen E, Weinstein M. Primary intestinal and thoracic lymphangiectasia: a response to antiplasmin therapy. Pediatrics 2002;109:1177-80.   DOI
16 Ingle GR, Sievers TM, Holt CD. Sirolimus: continuing the evolution of transplant immunosuppression. Ann Pharmacother 2000;34:1044-55.   DOI
17 Blackstone MM, Mittal MK. The edematous toddler: a case of pediatric Menetrier disease. Pediatr Emerg Care 2008;24:682-4.   DOI
18 Asakura H, Miura S, Morishita T, Aiso S, Tanaka T, Kitahora T, et al. Endoscopic and histopathological study on primary and secondary intestinal lymphangiectasia. Dig Dis Sci 1981;26:312-20.   DOI
19 Rivet C, Lapalus MG, Dumortier J, Le Gall C, Budin C, Bouvier R, et al. Use of capsule endoscopy in children with primary intestinal lymphangiectasia. Gastrointest Endosc 2006;64:649-50.   DOI
20 Ross AC, Caballero B, Cousins RJ, Tucker KL, Ziegler TR. Modern nutrition in health and disease. 11th ed. Philadelphia: Lippincott Williams & Wilkins, 2012.
21 Suresh N, Ganesh R, Sankar J, Sathiyasekaran M. Primary intestinal lymphangiectasia. Indian Pediatr 2009;46:903-6.
22 Kwon Y, Kim ES, Choe YH, Hyun D, Kim MJ. Therapeutic lymphatic embolization in pediatric primary intestinal lymphangiectasia. Yonsei Med J 2021;62:470-3.   DOI
23 Maleux G, Storme E, Cools B, Heying R, Boshoff D, Louw JJ, et al. Percutaneous embolization of lymphatic fistulae as treatment for protein-losing enteropathy and plastic bronchitis in patients with failing Fontan circulation. Catheter Cardiovasc Interv 2019;94:996-1002.   DOI
24 Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004;43:83-95.   DOI
25 Suehiro K, Morikage N, Murakami M, Yamashita O, Hamano K. Late-onset primary intestinal lymphangiectasia successfully managed with octreotide: a case report. Ann Vasc Dis 2012;5:96-9.   DOI
26 Kuroiwa G, Takayama T, Sato Y, Takahashi Y, Fujita T, Nobuoka A, et al. Primary intestinal lymphangiectasia successfully treated with octreotide. J Gastroenterol 2001;36:129-32.   DOI
27 Baluk P, Yao LC, Flores JC, Choi D, Hong YK, McDonald DM. Rapamycin reversal of VEGF-C-driven lymphatic anomalies in the respiratory tract. JCI Insight 2017;2:e90103.   DOI
28 Ghobrial IM, Gertz M, LaPlant B, Camoriano J, Hayman S, Lacy M, et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28:1408-14.   DOI
29 Hollis IB, Reed BN, Moranville MP. Medication management of cardiac allograft vasculopathy after heart transplantation. Pharmacotherapy 2015;35:489-501.   DOI
30 Ozeki M, Hori T, Kanda K, Kawamoto N, Ibuka T, Miyazaki T, et al. Everolimus for primary intestinal lymphangiectasia with protein-losing enteropathy. Pediatrics 2016;137:e20152562.   DOI
31 Lee EW, Shin JH, Ko HK, Park J, Kim SH, Sung KB. Lymphangiography to treat postoperative lymphatic leakage: a technical review. Korean J Radiol 2014;15:724-32.   DOI
32 Wyllie R, Hyams JS, Kay M. Pediatric gastrointestinal and liver disease. 4th ed. Philadelphia: Elsevier/ Saunders, 2011.
33 Wilkinson P, Pinto B, Senior JR. Reversible protein-losing enteropathy with intestinal lymphangiectasia secondary to chronic constrictive pericarditis. N Engl J Med 1965;273:1178-81.   DOI
34 Kwon Y, Kim ES, Choe YH, Kim MJ. Individual approach for treatment of primary intestinal lymphangiectasia in children: single-center experience and review of the literature. BMC Pediatr 2021;21:21.   DOI
35 Wagner MJ, Cranmer LD, Loggers ET, Pollack SM. Propranolol for the treatment of vascular sarcomas. J Exp Pharmacol 2018;10:51-8.   DOI
36 Prasad D, Srivastava A, Tambe A, Yachha SK, Sarma MS, Poddar U. Clinical Profile, response to therapy, and outcome of children with primary intestinal lymphangiectasia. Dig Dis 2019;37:458-66.   DOI
37 Liviskie CJ, Brennan CC, McPherson CC, Vesoulis ZA. Propranolol for the treatment of lymphatic malformations in a neonate - a case report and review of literature. J Pediatr Pharmacol Ther 2020;25:155-62.   DOI
38 Poralla C, Specht S, Born M, Muller A, Bartmann P, Muller A. Treatment of congenital generalized lymphangiectasia with propranolol in a preterm infant. Pediatrics 2014;133:e439-42.   DOI
39 Mine K, Matsubayashi S, Nakai Y, Nakagawa T. Intestinal lymphangiectasia markedly improved with antiplasmin therapy. Gastroenterology 1989;96:1596-9.   DOI
40 Chen E, Itkin M. Thoracic duct embolization for chylous leaks. Semin Intervent Radiol 2011;28:63-74.   DOI
41 Reichlin S. Secretion of somatostatin and its physiologic function. J Lab Clin Med 1987;109:320-6.